Zobrazeno 1 - 10 of 82 pro vyhledávání: '"Simon Pacey"'
1
Akademický článek
A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
Autor: Tristan Barrett, Simon Pacey, Kelly Leonard, Jerome Wulff, Ionut-Gabriel Funingana, Vincent Gnanapragasam
Publikováno v: European Urology Open Science, Vol 38, Iss , Pp 17-24 (2022)
Background: Active surveillance (AS) is a preferred management option for men with prostate cancer with favourable prognosis. However, nearly half of men on AS switch to treatment within 5 years, so therapeutic strategies to prevent or delay disease
Externí odkaz: https://doaj.org/article/7a238cec1f2c4a68acfa08e379669d70
Zobrazit plný text záznamu
2
Akademický článek
Tumor necrosis factor receptor‐2 signaling pathways promote survival of cancer stem‐like CD133+ cells in clear cell renal carcinoma
Autor: John R. Bradley, Jun Wang, Simon Pacey, Anne Y. Warren, Jordan S. Pober, Rafia S. Al‐Lamki
Publikováno v: FASEB BioAdvances, Vol 2, Iss 2, Pp 126-144 (2020)
Abstract Clear cell renal cell carcinoma (ccRCC) contains cancer stem‐like cells (CSCs) that express CD133 (ccRCC‐CD133+). CSCs are rarely in cell cycle and, as nonproliferating cells, resist most chemotherapeutic agents. Previously, we reported
Externí odkaz: https://doaj.org/article/d5953b34895e4de6b93851e80efc1895
Zobrazit plný text záznamu
3
Akademický článek
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
Autor: Peter W. Szlosarek, MD, PhD, Melissa M. Phillips, MD, PhD, Iuliia Pavlyk, PhD, Jeremy Steele, MD, Jonathan Shamash, MD, James Spicer, MD, PhD, Sanjeev Kumar, MD, Simon Pacey, MD, PhD, Xiaoxing Feng, PhD, Amanda Johnston, PhD, John Bomalaski, MD, Graeme Moir, MD, Kelvin Lau, MD, Stephen Ellis, MD, Michael Sheaff, MD
Publikováno v: JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100093- (2020)
Introduction: Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates pemetrexed (Pem) cytotoxicity in argininosuccinate synthetase 1 (ASS1)–deficient malignant pleural mesothelioma (MPM). We conducted a phase 1 dose-expansion study at th
Externí odkaz: https://doaj.org/article/b61eaabe82a64253a698a897597a8afc
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje